MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This policy covers NGS testing (both LDTs and FDA-approved/cleared tests) when used for diagnosis, characterization, or management of myeloid malignancies and suspected myeloid neoplasms per NCD 90.2 and MAC discretion. It explicitly excludes solid tumor testing, ctDNA testing, germline testing, and other non-myeloid cancer-related NGS uses; documentation and any prior authorization must follow NCD 90.2 and MAC requirements.

"Coverage is allowed for next-generation sequencing (NGS) clinical laboratory tests, including lab-developed tests (LDTs) and FDA-approved or -cleared tests, when performed for diagnosis, characteri..."

Sign up to see full coverage criteria, indications, and limitations.